The Role of Immunohistochemistry for Primary Oral Diagnosis in a Brazilian Oral Pathology Service.
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
Historique:
received:
23
09
2020
accepted:
03
06
2021
pubmed:
29
7
2021
medline:
8
3
2022
entrez:
28
7
2021
Statut:
ppublish
Résumé
A proper antibody panel selection is one of the most important factors to reach an adequate diagnosis in challenging cases. This retrospective study was designed to determine the contribution of immunohistochemistry (IHC) in the primary diagnosis of oral diseases in one of the main services of oral pathology in the State of São Paulo, Brazil, and to identify the most common antibodies used, and recommend diagnostic algorithms based on our experience with challenging lesions. A total of 1698 IHC stains were performed in 401 cases from a total of 28,804 cases received from public dental clinics and private dental practitioners within a period of 13 years, representing a frequency of 1.4% of IHC solicitations. Among these, 112 (28%) were mandatory to reach a final diagnosis and 255 (63.6%) were confirmative. In 34 (8.4%) cases, it was not possible to reach a conclusive/final diagnosis, even with IHC. Regarding the nature of the lesions, 210 (52.3%) were benign, 163 (40.6%) were malignant tumors, 13 (3.2%) were reactive, 10 (2.5%) were premalignant, and 5 (1.2%) were lesions of uncertain malignancy. Small amount of tissue of some incisional biopsies, overlapping features of spindle cell lesions (epithelial, neural, melanocytic, smooth muscle, endothelial, and fibroblastic/myofibroblastic cell differentiation), and overlapping features of salivary gland lesions were the most frequent challenges in which IHC stains were requested. Spindle cell lesions were the most frequent (22%) among all cases that required IHC to reach a final diagnosis. The implementation of IHC for routine practice requires a wide range of markers, proper antibody selection, and knowledge to interpret the subjectivity of staining. The inherent limitation of incisional biopsies was pointed as a reason to inconclusive diagnosis, despite a wide range of antibodies that our laboratory displays.
Identifiants
pubmed: 34320560
doi: 10.1097/PAI.0000000000000960
pii: 00129039-202111000-00010
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
781-790Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Ajura AJ, Sumairi I, Lau SH. The use of immunohistochemistry in an oral pathology laboratory. Malays J Pathol. 2007;29:101–105.
Fisher C. Immunohistochemistry in diagnosis of soft tissue tumors. Histopathology. 2011;58:1001–1012.
Barra MB. O uso da imunoistoquímica no diagnóstico−Indicações e limitações [The use of immunohistochemistry: indications and limitations]. Rev Assoc Med Rio Grande Do Sul. 2006;50:173–184.
Oliveira e Silva KR, Siqueira ALL, Caldeira PC, et al. Profile of usage of a reference diagnostic service on oral pathology: a 10-year evaluation. BMC Health Serv Res. 2014;14:653.
Leong A-Y, Wright J. The contribution of immunohistochemical staining in tumor diagnosis. Histopathology. 1987;11:1295–1305.
Li LT, Jiang G, Chen Q, et al. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11:1566–1572.
Nagao T, Sato E, Inoue R, et al. Immunohistochemical analysis of salivary gland tumors: application for surgical pathology practice. Acta Histochem Cytochem. 2012;45:269–282.
Sams RN, Gnepp DR. P63 expression can be used in differential diagnosis of salivary gland acinic cell and mucoepidermoid carcinomas. Head Neck Pathol. 2013;7:64–68.
Rooper LM. Challenges in minor salivary gland biopsies: a practical approach to problematic histologic patterns. Head Neck Pathol. 2019;13:476–484.
Altemani A, Martins MT, Freitas L, et al. Carcinoma ex pleomorphic adenoma (CXPA): Immunoprofile of the cells involved in carcinomatous progression. Histopathology. 2005;46:635–641.
Buchner A, Merrell PW, Carpenter WM. Relative frequency of central odontogenic tumors: a study of 1,088 cases from Northern California and comparison to studies from other parts of the world. J Oral Maxillofac Surg. 2006;64:1343–1352.
Hertog D, van der Waal I. Ameloblastoma of the jaws: a critical reappraisal based on a 40-years single institution experience. Oral Oncol. 2010;46:61–64.
Loyola AM, Cardoso SV, de Faria PR, et al. Ameloblastic carcinoma: a Brazilian collaborative study of 17 cases. Histopathology. 2016;69:687–701.
Hunter KD, Speight PM. The diagnostic usefulness of immunohistochemistry for odontogenic lesions. Head Neck Pathol. 2014;8:392–399.
Prescott RJ, Wells S, Bisset DL, et al. Audit of tumour histopathology reviewed by a regional oncology centre. J Clin Pathol. 1995;48:245–249.
Siqueira SC, Alves VF, Beitler B, et al. Contribution of Immunohistochemistry to Small B-Cell. Appl Immunohistochem Mol Morphol. 2006;14:1–6.
Hsiao S-C, Cortada IR, Colomo L, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology. 2012;61:685–693.
Garrington GE, Scofield HH, Cornyn J, et al. Osteosarcoma of the jaws. Analysis of 56 cases. Cancer. 1967;20:377–391.
Doval DC, Kumar RV, Kannan V, et al. Osteosarcoma of the jaw bones. Br J Oral Maxillofac Surg. 1997;35:357–362.
Akpolat N, Yildirim H. Sacral chondroblastic osteosarcoma misdiagnosed as chondrosarcoma and chordoma. Turk J Med Sci. 2007;37:243–249.
Kumaravelu C, Sathya Kumar D, Chakravarthy C, et al. Chondroblastic osteosarcoma of maxilla: a case report and review of literature. J Maxillofac Oral Surg. 2009;8:290–293.
Nawa G, Ueda T, Mori S, et al. Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas. Int J Cancer. 1996;69:86–91.
Aldojain A, Jaradat J, Summersgill K, et al. Ectomesenchymal chondromyxoid tumor: a series of seven cases and review of the literature. Head Neck Pathol. 2015;9:315–322.
Schneider N, Fisher C, Thway K. Ossifying fibromyxoid tumor: morphology, genetics, and differential diagnosis. Ann Diagn Pathol. 2016;20:52–58.
Pires FR, Abrahão AC, Cabral MG, et al. Clinical, histological and immunohistochemical features of ectomesenchymal chondromyxoid tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108:914–919.
Allen C. The ectomesenchymal chondromyxoid tumor: a review. Oral Dis. 2008;14:390–395.
Truschnegg A, Acham S, Kqiku L, et al. Ectomesenchymal chondromyxoid tumor: a comprehensive updated review of the literature and case report. Int J Oral Sci. 2018;10:4.
Kato MG, Erkul E, Brewer KS, et al. Clinical features of ectomesenchymal chondromyxoid tumors: a systematic review of the literature. Oral Oncol. 2017;67:192–197.
Hirshberg A, Berger R, Allon I, et al. Metastatic tumors to the jaws and mouth. Head Neck Pathol. 2014;8:463–474.
Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379:1428–1435.
Jensen M, Nielsen O, Johansen P, et al. Immunohistochemistry in tumor diagnosis. External quality assessment of 13 Departments of Pathology in Western Denmark. Appl Immunohistochem. 1997;5:35–44.